Bangavax

Last updated

Bangavax
Vaccine description
Target SARS-CoV-2
Vaccine type mRNA
Clinical data
Other namesBancovid
Routes of
administration
Intramuscular
ATC code
  • None

Bangavax, also known as Bancovid, is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited. [1] [2] [3] [4] [5] [6] The vaccine was initially called Bancovid. [7] On 23 November 2021, Globe Biotech has received ethical authorization from the Bangladesh Medical Research Council to conduct the first human trial. [8] [9]

History

On 2 July 2020, Globe Biotech Limited announced to be the first company from Bangladesh to have a COVID-19 vaccine under development. [1] The lone Bangladeshi company actually developed three COVID-19 vaccine candidates with different technologies. [10] The company named the mRNA based vaccine as Bancovid then renamed to Bangavax. [7] Globe Biotech took all the necessary steps from December 2020 to January 2021 to get the permission for ethical approval to conduct the first clinical trial of Bangavax. [4] The Bangladesh government has been criticized for not approval the vaccine even after months to conduct the first clinical trial without any explanation. [11]

Globe Biotech published full research data in Vaccine journal in May 2021. [12]

After five months of delays Bangladesh Medical Research Council conditionally grants ethical permission. Before proceeding to human trials, they have to apply the vaccine on monkeys or chimpanzees before proceeding to human trials. According to Md Harunur Rashid, chairman of Globe Biotech, "There are two types of mRNA vaccines: pure and modified. The modified one requires trials on monkeys. As Globe is making the pure mRNA one, trials on monkeys are unnecessary. Furthermore, there are no third-party CROs in the country that could conduct monkey trials. Regardless of the drawbacks, Globe will fulfil all the conditions that the government requires it to." [13]

As of February 2022, human clinical trials are underway and are expected to continue for at least six months. [14]

Related Research Articles

<span class="mw-page-title-main">CureVac</span> German bio-pharmaceutical company

CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to produce an immune response.

<span class="mw-page-title-main">Novavax</span> American biotechnology company

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.

Arcturus Therapeutics is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed a novel, potent, and safe RNA therapeutics platform called Lunar, a proprietary lipid-enabled delivery system for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides (ASO), and microRNA.

Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria, with other offices in France, Canada and the United States.

<span class="mw-page-title-main">COVID-19 pandemic in Bangladesh</span> Ongoing COVID-19 viral pandemic in Bangladesh

The COVID-19 pandemic in Bangladesh is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Bangladesh in March 2020. The first three known cases were reported on 8 March 2020 by the country's epidemiology institute, IEDCR. Since then, the pandemic has spread day by day over the whole nation and the number of affected people has been increasing. Bangladesh is the second most affected country in South Asia, after India.

<span class="mw-page-title-main">Bharat Biotech</span> Indian multinational biotechnology company and vaccine manufacturer

Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in the city of Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

<span class="mw-page-title-main">Covaxin</span> Vaccine against COVID-19

Covaxin is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

<span class="mw-page-title-main">Janssen COVID-19 vaccine</span> Vaccine against COVID-19

The Janssen COVID‑19 vaccine, sold under the brand name Jcovden, is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson.

<span class="mw-page-title-main">COVID-19 vaccination in India</span> Immunisation programme against COVID-19 in India

India began administration of COVID-19 vaccines on 16 January 2021. As of 2 December 2022, India has administered over 2.19 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines. In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering the urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">Inovio COVID-19 vaccine</span> COVID-19 vaccine candidate

Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.

<span class="mw-page-title-main">ARCT-021</span> Vaccine candidate against COVID-19

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

<span class="mw-page-title-main">PTX-COVID19-B</span> Vaccine candidate against SARS-CoV-2 (COVID-19)

PTX-COVID19-B is a messenger RNA (mRNA)-based COVID-19 vaccine, a vaccine for the prevention of the COVID-19 disease caused by an infection of the SARS-CoV-2 coronavirus, created by Providence Therapeutics—a private Canadian drug company co-founded by Calgary, Alberta-based businessman Brad T. Sorenson and San Francisco-based Eric Marcusson in 2013. A team of eighteen working out of Sunnybrook Research Institute in Toronto, Ontario developed PTX-COVID19-B in less than four weeks, according to the Calgary Herald. Human trials with sixty volunteers began on January 26, 2021 in Toronto.

iNCOVACC Vaccine candidate against COVID-19

iNCOVACC is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, American company Precision Virologics and the Washington University School of Medicine in St Louis, Missouri, United States.

<span class="mw-page-title-main">Walvax COVID-19 vaccine</span> Vaccine candidate against COVID-19

AWcorna, originally termed ARCoV and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. In contrast to other mRNA COVID vaccines, such as those by Pfizer-BioNtech and Moderna, this vaccine primarily targets the Sars-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein. It is approved for Phase III trials in China, Mexico, Indonesia, and Nepal.

<span class="mw-page-title-main">HGC019</span> Vaccine candidate against COVID-19

HGC019 is a mRNA based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.

<span class="mw-page-title-main">COVID-19 vaccination in Bangladesh</span> Immunisation programme against COVID-19 in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

<span class="mw-page-title-main">ARCT-154</span> Vaccine candidate against COVID-19

ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span>

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

References

  1. 1 2 "Globe Biotech's Covid-19 vaccine 'BANCOVID' listed by WHO". Daily Sun. 17 October 2020. Archived from the original on 30 April 2021. Retrieved 28 April 2021.
  2. "'Bangavax' to get approval within a week". The Daily Observer. 25 April 2021. Retrieved 28 April 2021.
  3. "Globe Biotech applies for clinical trial". Prothom Alo. 17 January 2021. Retrieved 28 April 2021.
  4. 1 2 "Globe Biotech yet to get BMRC nod for human trials". Dhaka Tribune. 22 February 2021. Archived from the original on 29 April 2021. Retrieved 28 April 2021.
  5. Sumon S (8 January 2021). "Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". Arab News. Archived from the original on 9 January 2021. Retrieved 28 April 2021.
  6. Baray JC, Khan MM, Mahmud A, Islam MJ, Myti S, Ali MR, et al. (January 2020). "BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response". bioRxiv. doi:10.1101/2020.09.29.319061. S2CID   222127616.
  7. 1 2 "Globe Biotech to produce vaccine candidate for clinical trial". The Financial Express. Dhaka. 6 January 2021. Retrieved 28 April 2021.
  8. "Bangavax gets BMRC approval to start human trials". Dhaka Tribune. 23 November 2021. Retrieved 23 November 2021.
  9. "Bangavax gets ethical permission for human trial". The Daily Star. 23 November 2021. Retrieved 23 November 2021.
  10. "3 Covid-19 vaccine candidates by Bangladesh's Globe Biotech enlisted in WHO draft landscape". The Daily Star. 17 October 2020. Archived from the original on 24 January 2021. Retrieved 4 May 2021.
  11. Masum O (6 May 2021). "Bangavax first buzzed with hope, then fizzled". bdnews24.com. Archived from the original on 9 May 2021. Retrieved 6 May 2021.
  12. Nag K, Baray JC, Khan MR, Mahmud A, Islam J, Myti S, et al. (18 May 2021). "An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose". Vaccine X . 39 (23): 3745–3755. doi: 10.1016/j.vaccine.2021.05.035 . PMC   8130517 . PMID   34039497.
  13. "Bangavax Covid vaccin: BMRC gives fresh conditions to Globe Biotech for human trials". Dhaka Tribune. 16 June 2021. Archived from the original on 28 June 2021. Retrieved 16 June 2021.
  14. "Global south moves towards vaccine sovereignty". New Age. 19 February 2022.